冠状动脉抽血和ST升高心肌梗塞患者:动脉样硬化是否影响外科治疗和长期预后?
在PubMed上查看摘要
概括
此摘要是机器生成的。根据冠状动脉硬化存在的情况,ST升高心肌梗塞 (STEMI) 和冠状动脉脱动 (CAE) 患者的治疗结果不同. 这项研究突出了不同的围绕程序特征,影响治疗策略.
科学领域
- 心脏病学
- 干预心脏病学
- 血管生物学
背景情况
- 冠状动脉脱动 (CAE) 影响ST升高心肌梗塞 (STEMI) 的程序结果.
- 在STEMI患者中,CAE与动脉硬性冠状动脉疾病 (ACAD) 之间的关系尚不清楚.
- 了解这些关联对于优化患者管理至关重要.
研究的目的
- 为了比较CAE的STEMI患者的临床和程序特征.
- 通过同时存在的ACAD的存在或不存在来分层评估STEMI患者的结果.
- 确定单独的CAE和ACAD的CAE之间围绕程序管理和结果的差异.
主要方法
- 分析了一组148名患有外泄性心脏病相关动脉的STEMI患者,这些患者接受了初级皮肤干预 (PCI).
- 患者被分为两个组:单独的CAE (n=74) 和与ACAD同时存在的CAE (n=74).
- 临床数据,手术细节和3年随访结果在两组之间进行了比较.
主要成果
- 与单独的CAE患者相比,CAE和ACAD患者年龄较大,冠状动脉血管造形和支架更频繁.
- 在CAE与ACAD组中观察到较少的远端栓塞趋势.
- 两组之间心脏酶水平,左心室喷射率或3年内无重大心血管不良事件 (MACE) 发生率没有显著差异.
结论
- 根据冠状动脉样硬化存在的情况,患有外泄性心脏病相关动脉的STEMI患者表现出明显的周围过程特征.
- 这些发现表明,同时存在的ACAD会影响STEMI患者的程序干预.
- 需要进一步的研究,以确定这些患者在出院时的最佳治疗策略.
相关概念视频
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

